Physician profile
Michael E Gutierrez
NPI 1518957927
$3,385.81
in general payments reported to CMS, 2019-2025
26 companies · $194 in 2025
The $194 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2020: $701 · 2021: $690 · 2022: $199 · 2023: $557 · 2024: $265 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,016.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,306.75 | 2019-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $495.73 | 2019-2025 | |
| Amgen INC. | $206.49 | 2019-2023 | Repatha |
| Boston Scientific Corporation | $173.30 | 2023-2024 | |
| Pfizer INC. | $151.46 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $148.60 | 2019-2021 | |
| Medtronic, INC. | $138.46 | 2023-2025 | Ellipsys Vascular Access System, Harmony, Linq II |
| E.R. Squibb & Sons, L.L.C. | $96.42 | 2021-2025 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.99 | 2019-2021 | |
| Impulse Dynamics (USA) INC. | $79.71 | 2023 | Optimizer |
| Ekos Corporation | $77.32 | 2019 | |
| Tactile Systems Technology INC | $56.06 | 2019-2022 | |
| Amarin Pharma, INC. | $52.48 | 2020-2021 | |
| Bard Peripheral Vascular, INC. | $43.21 | 2021-2023 | Venovo |
| Scpharmaceuticals INC. | $34.85 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $33.19 | 2025 | Amvuttra |
| Medtronic Vascular, INC. | $32.45 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $26.69 | 2019-2022 | |
| Brainsway USA INC | $23.38 | 2023 | |
| Novo Nordisk INC | $22.47 | 2024 | Ozempic |
| Lexicon Pharmaceuticals, INC. | $20.98 | 2023 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.43 | 2024-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $13.39 | 2019 | |
| Merck Sharp & Dohme LLC | $12.89 | 2023 | Verquvo |
| Genzyme Corporation | $12.15 | 2019 | |
| Cvrx, INC. | $10.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gutierrez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.